Douglass Winthrop Advisors LLC Sells 6,058 Shares of Becton, Dickinson and Company $BDX

Douglass Winthrop Advisors LLC cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 74.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,034 shares of the medical instruments supplier’s stock after selling 6,058 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Becton, Dickinson and Company were worth $381,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BDX. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. Oppenheimer Asset Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 71.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after acquiring an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 88.2% during the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after acquiring an additional 2,715 shares during the last quarter. Belpointe Asset Management LLC purchased a new position in shares of Becton, Dickinson and Company during the third quarter worth about $650,000. Finally, Assetmark Inc. grew its holdings in shares of Becton, Dickinson and Company by 49.5% during the third quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock worth $42,294,000 after purchasing an additional 74,795 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BDX shares. TD Cowen raised their target price on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 11th. Bank of America lifted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Finally, Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $195.46.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,416 shares of company stock valued at $674,693 over the last 90 days. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $159.37 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a fifty day moving average of $190.72 and a 200-day moving average of $190.28. The stock has a market capitalization of $45.38 billion, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 11.83 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter last year, the company earned $3.43 EPS. The firm’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.